Available online 16 July 2017 The Liver X Receptors (LXRs) are oxysterol-activated transcription factors that upregulate a suite of genes that together promote coordinated mobilization of excess cholesterol from cells and from the body. The LXRs, like other nuclear receptors, are anti-inflammatory, inhibiting signal-dependent induction of pro-inflammatory genes by nuclear factor-κB, activating protein-1, and other transcription factors. Synthetic LXR agonists have been shown to ameliorate atherosclerosis and a wide range of inflammatory disorders in preclinical animal models. Although this has suggested potential for application to human disease, systemic LXR activation is complicated by hepatic steatosis and hypertriglyceridemia, consequences of lipogenic gene induction in the liver by LXRα. The past several years have seen the development of multiple advanced LXR therapeutics aiming to avoid hepatic lipogenesis, including LXRβ-selective agonists, tissue-selective agonists, and transrepression-selective agonists. Although several synthetic LXR agonists have made it to phase I clinical trials, none have progressed due to unforeseen adverse reactions or undisclosed reasons. Nonetheless, several sophisticated pharmacologic strategies, including structure-guided drug design, cell-specific drug targeting, as well as non-systemic drug routes have been initiated and remain to be comprehensively explored. In addition, recent studies have identified potential utility for targeting the LXRs during therapy with other agents, such as glucocorticoids and rexinoids. Despite the pitfalls encountered to date in translation of LXR agonists to human disease, it appears likely that this accelerating field will ultimately yield effective and safe applications for LXR targeting in humans.
Introduction
First identified in the mid-1990s as orphan members of the nuclear receptor (NR) superfamily, the Liver X Receptors (LXRα and LXRβ) were soon recognized to be activated by endogenous oxysterols (i.e., oxidized cholesterol), and to induce a suite of target genes that correct sterol overload by promoting cholesterol disposal from the cell and from the body Peet, Janowski, & Mangelsdorf, 1998) . The identification of LXRs as master regulators of cholesterol sensing and handling has led to sustained efforts to develop synthetic LXR agonists that might ultimately prove therapeutic against human atherosclerosis. Interest in the LXRs as drug targets has been further elevated by the discovery that they, like other NRs (e.g., the glucocorticoid receptor), have potent anti-inflammatory effects (Steffensen, Jakobsson, & Gustafsson, 2013; Zelcer & Tontonoz, 2006) . Indeed, pharmacological activation of LXR has now been shown not only to reduce atherosclerosis in rodent models but also to ameliorate pathology in a wide range of preclinical inflammatory disease models, ranging from atopic dermatitis, to acute lung injury, autoimmune disease, and neurodegenerative disorders (A-Gonzalez et al., 2009; Cui et al., 2012; Fowler et al., 2003; Smoak et al., 2008) . Remarkably, LXR agonists also show early promise in models of cancer and viral infection, two disorders in which disrupted cellular cholesterol homeostasis has been shown to drive pathogenesis (Fessler, 2016; Lin, Vedin, & Steffensen, 2016; Ramezani et al., 2015) .
Development of LXR agonists as therapeutics has proven quite challenging due to their precipitation of hepatic steatosis and hypertriglyceridemia, effects generally thought to arise from activation of LXRα in the liver. This has led the field to a range of innovative strategies, including LXRβ-selective agonists, tissue-selective LXR agonists, and LXR transrepression-selective agents. Further hurdles have arisen in the form of known differences between rodent and human physiology as well as unforeseen differences between non-human primates and humans. To date, the four LXR-targeted drugs that have made it to phase I clinical trials have unfortunately not advanced further. Nonetheless, it appears likely that with further refinement of advanced LXR therapeutics and evolving insights into the role of the LXRs in specialized cell types, opportunities for successful targeting of the LXRs in human disease will ultimately be realized.
Background on the LXRs

Structural features and activation by ligands
LXRα (encoded by NR1H3 on chromosome 11 in humans) and LXRβ (encoded by NR1H2 on chromosome 19 in humans) are ligandactivated transcription factors (i.e., NRs). LXRs are comprised of four principal functional domains: i) an N-terminal AF-1 activation domain; ii) a DNA-binding domain; iii) a ligand-binding domain; and iv) a Cterminal AF-2 domain that regulates transcription through interactions with co-activators and co-repressors (Ma et al., 2017) . The LXRs vary in tissue distribution, with LXRα expressed primarily in macrophages, intestine, liver, adipose, and kidney, whereas LXRβ is more ubiquitous (Repa et al., 2000) . This may create opportunities for targeted therapeutic strategies given that, for example, human lymphocytes express LXRβ but not LXRα (Bensinger et al., 2008) . Although human LXRα (447 amino acids) and LXRβ (460 amino acids) share 77% sequence homology and have just a single amino acid difference in their ligand-binding domains, their crystal structures have revealed a very flexible ligandbinding pocket (Farnegardh et al., 2003) . This perhaps explains the breadth of structurally dissimilar LXR ligands, including LXRα-and -β-selective agents, that have been identified or designed to date, and also suggests potential for rational design of LXR modulators. A further layer of LXR modulation is conferred by a wide range of regulatory post-translational modifications that have been identified for the LXR proteins, including SUMOylation, phosphorylation, acetylation, ubiquitination, and O-GlcNacylation (Jakobsson, Treuter, Gustafsson, & Steffensen, 2012) .
The major endogenous LXR agonists that have been identified to date are: i) oxysterols [i.e., 20(S)-, 22(R)-, 24(S)-, 25-, and 27-hydroxycholesterol; 24(S),25-epoxycholesterol; cholestenoic acid]; and ii) cholesterol biosynthetic intermediates [i.e., desmosterol, follicular fluid meiosis-activating sterol (FF-MAS), testis meiosis-activating sterol (T-MAS)] (Komati et al., 2017; . LXR-active oxysterols are generated from cholesterol substrate by endoplasmic reticulum (ER) enzymes (CYP46, CH25H) and mitochondrial enzymes (CYP27A1), or, in the case of 24(S),25-epoxycholesterol, as a shunt by-product off of the cholesterol synthesis pathway . Confirmation that oxysterols serve as native LXR activators in vivo was provided by the triple knockout mouse for Cyp46, Ch25h, and Cyp27a1, which was found to have deficient LXR-dependent gene expression in the liver in response to highcholesterol diet (Chen, Chen, Head, Mangelsdorf, & Russell, 2007) . Of interest, several exogenous, natural plant-derived compounds have also been shown to have activating (phytosterols, diterpenes, gynosaponin, honokiol, podocarpic acid, cyanidin) or inhibitory (riccardin C and F, naringenin) activity upon the LXRs -in many of these cases, via indirect mechanisms (Komati et al., 2017) . This may suggest that the LXR pathway also serves as a xenobiotic sensor.
As discussed below, the primary function of the LXRs is thought to be cholesterol homeostasis (i.e., correction of cholesterol overload). Target genes induced by LXRs mediate efflux of cholesterol from cells (e.g., the lipid transporters ATP Binding Cassette [ABC] A1 and ABCG1), reduction of cholesterol uptake into cells (e.g., inducible degrader of the low density lipoprotein receptor [IDOL] ), and excretion of cholesterol from the body (e.g., ABCG5/8 transporter in the biliary and intestinal epithelium). Interestingly, oxysterols and desmosterol serve as integrators of cellular cholesterol homeostasis, as they not only drive cholesterol efflux via LXR activation, but also coordinately suppress cholesterol accumulation by blocking activation of sterol response element binding protein (SREBP)-2, a master regulatory transcription factor that upregulates the low density lipoprotein receptor (LDLR) and the enzymes of the cholesterol biosynthesis pathway (Fessler, 2016) .
In vivo, some oxysterols are thought to be produced predominantly in specific tissues, where they mediate organ-specific functions. For example, 24(S)-hydroxycholesterol derives largely from CYP46-expressing neurons in the central nervous system, where it serves key functions in health and disease (Zhang & Liu, 2015) . Cholestenoic acid is thought largely to derive from CYP27A1-expressing alveolar macrophages in humans (Babiker et al., 1999) . These two oxysterols circulate at substantial concentrations in mice and humans. This suggests that oxysterol diffusion from brain and lung may serve as a direct pathway for tissue sterol export, and also that oxysterols may possibly mediate endocrine functions in vivo. While in most cases it remains unclear which LXR agonists are relevant in specific cell types during disease, it was recently shown that desmosterol plays a key role in LXRdependent gene expression in macrophage foam cells (Spann et al., 2012) .
Several LXR ligands also have activity on other NRs as well as immune receptors, suggesting integration of LXR with other endocrine and immune networks. For example, 27-hydroxycholesterol is also a selective estrogen receptor (ER) modulator (DuSell, Umetani, Shaul, Mangelsdorf, & McDonnell, 2008) , 25-hydroxycholesterol is an ERα activator (Lappano et al., 2011) , and 24(S)-hydroxycholesterol is a retinoid orphan receptor (ROR)-α and ROR-γ inverse agonist . Desmosterol was recently identified as an agonist of RORγt, the master regulator of T helper 17 cell differentiation (Hu et al., 2015) . In some cases, oxysterols have been shown to have remarkably pleiotropic activity that goes well beyond NRs. For example, in different settings, 25-hydroxycholesterol suppresses inflammasomes thereby inhibiting interleukin-1β production , augments pro-inflammatory gene transcription through supporting binding of AP-1 to promoters (Gold et al., 2014) , and acts as a neutrophil chemoattractant through ligating the chemokine receptor CXCR2 (Raccosta et al., 2013) . LXR-active oxysterols also communicate as metabolic intermediates with other signaling networks. Thus, oxidation of 25-hydroxycholesterol by Cyp7b converts it into 7α,25-hydroxycholesterol, a key chemoattractant that positions dendritic cells and B cells in the spleen via the receptor Gpr183 (Cyster, Dang, Reboldi, & Yi, 2014) . Oxidation of 27-hydroxycholesterol by Cyp7b converts it into a RORγt agonist (Soroosh et al., 2014) .
Two non-steroidal, synthetic, dual LXRα/β full agonists that were developed in the early 2000s have now been used widely by the field to probe LXR biochemistry. The first, TO901317, also has activity on several other NRs, including farnesoid X receptor and pregnane X receptor (agonist), and RORα and -γ (inverse agonist), somewhat limiting its utility (Guillemot-Legris, . The second, GW3965, is much more specific for LXR. A key difference between native oxysterol LXR agonists and synthetic LXR agonists such as these is that the latter do not have coordinated activity on SREBPs; thus, LXR gene induction by these compounds is non-physiologically dissociated from inhibition of lipid synthesis. As discussed below, further advances have been made in recent years in the design of more selective LXR-active compounds, including some that do also suppress SREBP activation.
Endogenous LXR antagonists that have been identified include polyunsaturated fatty acids, arachidonic acid, prostaglandin F 2α , and 5α,6α-epoxycholesterol (Komati et al., 2017) . The precise mechanism(s) of LXR inhibition remain to be defined in some of these cases. While the physiologic relevance of these antagonists in vivo also remains largely unclear, it has been shown that 25-hydroxycholesterol acquires antagonistic activity for LXR upon sulfation (i.e., into 25-hydroxycholesterol-3-sulfate) by the sulfotransferase Sult2b1b (Ma et al., 2008) . Remarkably, Sult2b1b-mediated inactivation of LXR agonistic oxysterols has been shown to be a key event during T cell proliferation (Bensinger et al., 2008) , and may also promote pro-tumorigenic cholesterol accumulation in cancer cells by uncoupling LXR-dependent sterol sensing from cellular sterol burden (Bovenga, Sabba, & Moschetta, 2015) .
Genomic binding and mechanisms of target gene transactivation
Transactivation of target genes by LXRs requires permissive heterodimerization of LXR with retinoid X receptor (RXR), a retinoic acid-activated NR that dimerizes with several members of the NR superfamily. LXR/RXR dimers bind to so-called 'DR4'-type LXR response elements (LXREs) in target gene promoters, a binding site composed of a repeating 6-mer core sequence of 5′-AGGTCA-3′ separated by a spacer of any 4 nucleotides (Pehkonen et al., 2012) . In macrophages, binding of LXR to promoters and enhancers requires initial chromatin remodeling by the pioneer factor PU.1 . While recent genome-wide studies support the DR4-type element as the major binding motif for LXR (Pehkonen et al., 2012) , it appears that a substantial percentage of LXR target genes do not have a well-defined DR4 element (Boergesen et al., 2012; Heinz et al., 2010) . Also, recent studies indicate that some LXREs may downregulate target gene expression upon LXR binding; examples of such negatively regulated genes are CYP51A1 and FDFT1 (encoding lanosterol 14α-demethylase and squalene synthase, respectively, of the cholesterol synthesis pathway) (Wang et al., 2008) . Of interest, negative regulation at LXREs in the promoters for these two genes appears to be LXR ligand-specific, as downregulation is induced by oxysterols but not by TO901317 (Wang et al., 2008) . Further work will be necessary to define the identity and frequency of negative LXREs in the genome given that recent studies indicate that a substantial proportion of target genes are in fact downregulated in macrophages upon LXR activation (Pehkonen et al., 2012) .
The conventional model of LXR target gene transactivation holds that unliganded LXRs are tonically bound to LXREs and suppress transcription of target genes by recruiting co-repressors such as nuclear co-repressor 1 (NCoR1) and silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) (Jakobsson et al., 2012) (Fig. 1a) . Upon LXR ligation, co-repressors are cleared and exchanged for co-activators such as NR co-activator 1 (NCOA1) and activating signal co-integrator 2 (ASC2), leading to transcription. More recently, it has been recognized that this model, typified by the target gene ABCA1, may characterize just a subset of the LXR transcriptome. Recent genome-wide studies have indicated that in a majority of cases LXR may be recruited de novo to the promoters of target genes upon activation (Boergesen et al., 2012) . In the case of the target gene ABCG1, the co-regulator G-protein pathway suppressor 2 (GPS2) stabilizes an NCoR/histone deacetylase (HDAC)-3 co-repressor complex along with repressive histone 3 lysine 9 dimethylation in the inactive state, whereas, upon LXR ligation, GPS2 facilitates H3K9 de-methylation and recruitment of LXR (Jakobsson et al., 2009) (Fig. 1a) .
In many cases, LXRα and LXRβ appear to be largely interchangeable in transactivation, with their contribution determined by relative expression level. That said, in murine macrophages, LXRα may be more robust at transactivation and LXRβ more potent at basal target repression (Bischoff et al., 2010) . Also, CD5L/Aim has been identified as an LXRα-specific target gene (Joseph et al., 2004) . In vivo, important systems-level differences have also been identified between the two LXRs. For example, LXRα and not LXRβ is required for development of splenic marginal zone macrophages in mice (A-Gonzalez et al., 2013).
Transrepression
LXR activation has also been shown to inhibit the signal-dependent induction of pro-inflammatory genes by transcription factors such as nuclear factor (NF)-κB, signal transducer and activator of transcription (STAT)-1, and activator protein (AP)-1, a mechanism known as 'transrepression' (Fig. 1b) . In macrophages and hepatocytes, LXR agonists induce HDAC4-dependent conjugation of LXR with SUMO-2/3 at specific lysine residues in the LXR ligand-binding domain; SUMOylated LXR then binds as a monomer to the NCoR-SMRT co-repressor complex and prevents its signal-dependent clearance from the promoters of proinflammatory genes (Ghisletti et al., 2007 (Ghisletti et al., , 2009 Jakobsson et al., 2012) . LXR thereby suppresses LPS induction of inducible nitric oxide synthase (iNOS), interleukin (IL)-1β, and other genes in macrophages by preventing co-repressor dismissal (Ghisletti et al., 2009) ; of interest, transrepression by LXR appears to be selective as it does not inhibit iNOS induction by the Toll-like Receptor (TLR)2 agonist Pam3CSK4 (Ghisletti et al., 2007) . In cultured hepatocytes as well as in vivo in the mouse, induction of acute phase response genes (i.e., serum amyloid A, haptoglobin) by cytokines is similarly suppressed by SUMOylated LXRβ (Venteclef et al., 2010) . Interestingly, in astrocytes, the LXRs transrepress interferon-γ-induced genes by yet a different mechanism, one that does not involve NCoR and that involves differential SUMOylation of the two LXR proteins (Lee et al., 2009) . Specifically, LXRα is SUMO2-conjugated by HDAC4, whereas LXRβ is SUMO1-conjugated by protein inhibitor of activated STAT1 (PIAS1); the two SUMOylated LXRs complex with phosphorylated STAT1 and prevent its binding to gene promoters (Lee et al., 2009) . Taken together, LXRs suppress pro-inflammatory gene induction through mechanisms that are distinct from those that they employ for target gene transactivation. This said, for the most part, the physiological relevance of LXR SUMOylation remains to be clearly demonstrated in vivo. Moreover, it has recently been shown that LXR-dependent repression of inflammatory genes requires both RXR and the LXR DNA-binding domain, and still functions despite mutation of LXR SUMOylation sites and knockdown of the SUMOylation machinery (Ito et al., 2015) . Given this, the SUMOylation model of LXR transrepression remains less well established than the transcriptional model, with less certain physiological significance and relevance.
Non-genomic mechanisms of LXR action
Recently, as is the case for some other NRs, non-genomic (non-transcriptional) mechanisms of action have also been identified for LXRβ (Fig. 1c) , further expanding the potential for selective manipulation of the LXRs in health and disease. However, it is important to acknowledge that, given the current relative paucity of publications in this area in comparison to the large number of reports on LXRβ as a nuclear transcription factor, non-genomic roles for LXRβ should be viewed with some caution until these findings are more widely replicated and their physiologic significance more firmly established. In colon cancer cells, , are the best characterized means of LXR activity in cells, whereas recently described non-genomic mechanisms (C) remain somewhat less well understood. In transactivation, two general models, represented by induction of the target genes ATP Binding Cassette (ABC)A1 and ABCG1, have been identified. For ABCA1, it is thought that LXR bound to promoter LXR response elements (LXREs) in the steady state tonically represses gene expression by recruiting co-repressors such as nuclear receptor co-repressor 1 (NCoR). Upon LXR ligand binding, co-repressors are shed in exchange for co-activators, driving gene expression. More recent studies suggest that for a majority of LXR targets including ABCG1, LXRs bind to LXREs only after ligand-induced activation and histone demethylation. In both of these models, LXR binds LXREs directly in the form of a heterodimer with retinoid X receptor (RXR). In the case of transrepression of pro-inflammatory genes (B), two general mechanisms of LXR action have been identified in macrophages/hepatocytes and astrocytes. In both cases, lysines in the ligand-binding domain of LXR are SUMOylated after LXR ligation. In the case of LPS-stimulated macrophages or cytokine-stimulated hepatocytes, SUMOylated LXR binds in monomeric form to a multimolecular corepressor complex, inhibiting release of co-repressors from gene promoters, thereby blocking gene expression. In astrocytes, SUMOylated LXRs inhibit transcription by blocking the binding of signal transducer and activator of transcription 1 (STAT1) to promoters. Recently, examples of non-genomic (extranuclear) LXRβ action have been identified, as shown in panel C. In colon cancer cells, cytoplasmic LXRβ drives NLRP3-and caspase-1-dependent pyroptotic cell death by inducing pannexin-1-mediated ATP release. In platelets, LXRβ inhibits kinase signaling to degranulation and aggregation downstream of the GPVI receptor. In endothelial cells, lipid raft-localized LXRβ mediates a signaling pathway to cell migration involving estrogen receptor (ER)-α and the kinase AKT. The relative importance of genomic and non-genomic mechanisms remains poorly understood. The distinct binding partners of LXRs in these various contexts, however, creates the exciting potential for targeted, potentially cell type-and gene-specific, pharmacologic interventions. eNOS, endothelial nitric oxide synthase; GPVI, glycoprotein VI; GPS2, G-protein pathway suppressor 2; HDAC, histone deacetylase; iNOS, inducible nitric oxide synthase; P2X7, P2X purinoceptor 7; PIAS1, protein inhibitor of STAT1; SAA, serum amyloid A; SUMO, small ubiquitin-like modifier; TBLR, transducin beta-like 1X-related protein 1; UBC9, SUMO-conjugating enzyme UBC9.
LXRβ, upon ligation, binds to and promotes activation of the plasma membrane channel pannexin-1, inducing ATP efflux and subsequent caspase-1-dependent pyroptotic cell death through a pathway involving the P2X7 purinergic receptor and the Nlrp3 inflammasome (Derangere et al., 2014) . Mislocalization of LXRβ to the cytoplasm in colon cancer cells (but not healthy colonic epithelia) may arise from their expression of an abnormal truncated form of RXRα which sequesters LXRβ to this compartment (Courtaut et al., 2015) . In endothelial cells, ligated LXRβ binds to ERα in lipid raft membrane microdomains, thereby initiating a raft-localized signaling cascade via ERα, phosphoinositide-3-kinase, and Akt to activation of endothelial NOS (Ishikawa et al., 2013) . In (anucleate) platelets, LXR agonists inhibit degranulation and aggregation through inducing interactions between LXRβ and signaling proteins immediately downstream of the collagen receptor GPVI (Ishikawa et al., 2013) . Additional studies will be required to define the relative importance of genomic vs. non-genomic roles for LXRβ in inflammatory disease, as well as whether LXRα participates in non-transcriptional signaling events.
LXR regulation of reverse cholesterol transport and atherosclerosis
The best-established role for the LXRs in physiology is in transcriptional activation of reverse cholesterol transport (RCT), the coordinated pathway in vivo that protects against atherosclerosis by promoting efflux and bodily excretion of excess cellular cholesterol (Fig. 2) . Many of the key proteins in RCT, including ABCA1, ABCG1, cholesteryl ester transfer protein (CETP), ABCG5, and ABCG8 are direct LXR target genes and are thus coordinately upregulated by LXR agonists (Jakobsson et al., 2012) . Cholesterol 7α hydroxylase (CYP7A1), the major enzyme of the classical pathway of bile acid synthesis, is an LXR target in mice but not humans.
The details of RCT have been covered in prior comprehensive reviews (Azzam & Fessler, 2012; . In brief, RCT is initiated in hepatocytes and enterocytes, where ABCA1-dependent lipidation of apolipoprotein (apo)A-I generates nascent pre-β high density lipoprotein (HDL) particles. Pre-β-HDL (and lipid-free apoA-I) serve as primary plasma acceptors for excess cellular cholesterol, acting, along with mature HDL, to induce cholesterol efflux from macrophages (and other parenchymal cells) in a manner facilitated by the lipid transporters ABCA1 and ABCG1. HDL-associated cholesterol is then cleared from the plasma through three alternate pathways. First, scavenger receptor B type I can mediate selective cholesterol ester uptake from HDL into hepatocytes. Second, CETP (present in humans, but not mice) facilitates transfer of cholesterol ester from HDL to very LDL (VLDL) and LDL, followed by LDL clearance by hepatocytes via LDLR. Lastly, apoB100 lipoprotein-derived cholesterol can also be cleared from the plasma by direct basolateral-to-apical transfer across enterocytes into the Fig. 2 . LXRs are master regulators of reverse cholesterol transport. The in vivo pathways for disposal of excess cellular -in this case, macrophage -cholesterol from the organism, so called 'reverse cholesterol transport,' are depicted. Proteins in green font are encoded by LXR target genes, and are thus upregulated by LXR agonists (note, however, that cytochrome P450 family 7 subfamily A member 1 [CYP7A1] is an LXR target in mice and not humans, and cholesteryl ester transfer protein [CETP] is expressed in humans but not mice). ATP Binding Cassette (ABC)A1 in enterocytes and hepatocytes generates plasma high density lipoprotein (HDL) by lipidation of plasma apolipoprotein (apo)A-I. HDL in turn induces cholesterol efflux from macrophages via cooperative interactions with ABCA1 and ABCG1. HDL-associated cholesterol can then either be cleared via hepatocyte scavenger receptor (SR)-BI, or transferred to apoB100-containing lipoproteins via CETP in exchange for triglyceride (TG). Finally, apoB100-lipoprotein cholesterol is cleared from the plasma either by hepatocyte low density lipoprotein receptor (LDLR), or by trans enterocyte transfer into the gut lumen, the so-called 'trans intestinal cholesterol excretion' (TICE) pathway. Hepatic cholesterol that is not used to assemble very LDL (VLDL) plasma particles can be excreted into the biliary system (and from there into the gut lumen), either via ABCG5/8-dependent transport as free cholesterol, or as bile acids, after conversion by CYP7A1. In enterocytes, LXR upregulates ABCA1 (driving HDL production) and ABCG5/8 (promoting cholesterol efflux into gut lumen), and downregulates Niemann Pick C1 like 1 (NPC1L1) protein (reducing uptake of luminal cholesterol). Taken together, enterocyte LXR increases plasma HDL, reduces cholesterol absorption, and promotes cholesterol excretion. Hepatic LXR increases plasma HDL and promotes biliary cholesterol excretion. Hepatic LXR also induces the lipogenic genes sterol response element binding protein (SREBP)-1c, fatty acid synthase (FAS), and stearoyl coA-desaturase (SCD)1, as well as inducible degrader of the LDLR (IDOL). In rodent models, treatment with LXR agonists drives fecal excretion of macrophage-derived cholesterol (i.e., RCT intestinal lumen, the so-called 'transintestinal cholesterol excretion' (TICE) pathway (Temel & Brown, 2015) . Hepatic cholesterol, deriving from HDL uptake from the plasma, diet (chylomicron remnant uptake), and/or in situ synthesis is either used to assemble VLDL particles for release into the plasma, or completes the RCT pathway via excretion into the biliary tract either as free cholesterol (via the biliary epithelial transporter ABCG5/ABCG8), or as bile acids (after processing by CYP7A1). ABCG5/ABCG8 expressed in intestinal epithelial cells also mediates cholesterol efflux directly into the gut lumen. Finally, gut luminal cholesterol is excreted from the body, thus completing the centripetal clearance of cellular cholesterol into the feces, if it escapes short-circuiting reabsorption into enterocytes mediated via Niemann-Pick C1-like 1 protein (NPC1L1). Of interest, LXR agonists reduce intestinal cholesterol absorption by downregulating NPC1L1 (Duval et al., 2006) and upregulating ABCG5/ABCG8 (Bonamassa & Moschetta, 2013) in the brush border. This enhances successful completion of RCT.
Extensive data now demonstrates that synthetic LXR agonists upregulate RCT and reduce atherosclerosis in preclinical models (Joseph et al., 2002; Naik et al., 2006; Tangirala et al., 2002) . Complex roles for both LXRα and LXRβ have now been identified at several sites in the RCT pathway, from peripheral macrophage to intestine, suggesting that multiple therapeutic strategies for activating LXRs to combat atherosclerosis may be available. As further detailed below, a selective strategy will almost certainly be necessary given that activation of hepatic LXRα (the predominant LXR in liver), induces hepatic steatosis and hypertrigycleridemia (through induction of hepatic SREBP-1c, fatty acid synthase, stearoyl-coA desaturase-1, and carbohydrateresponsive element-binding protein) and also increases plasma LDLcholesterol in non-human primates through IDOL-mediated degradation of hepatic LDLR (Ma et al., 2017) (Fig. 2) .
LXR-null mice have severe impairment of RCT (Tangirala et al., 2002) , whereas treatment of wild type mice with synthetic LXR agonists increases RCT (Naik et al., 2006) . A predominant role for LXRα in RCT was suggested by studies showing that LXRα-null mice on the proatherogenic Apoe-null background have severe tissue cholesterol overload and augmented atherosclerosis, whereas LXRβ-null counterparts do not (Bradley et al., 2007; Hong, Bradley, et al., 2012) . Similar findings were noted in Ldlr-null background mice on a Western diet, an alternate widely used model of atherosclerosis (Bischoff et al., 2010) . The impact of LXRα deletion on macrophage cholesterol overload appears to arise as a post-macrophage defect perhaps driven by altered hepatic gene expression given that macrophage cholesterol efflux is deficient in vivo but not ex vivo in LXRα-null mice (Hong, Bradley, et al., 2012) . In support of this, hepatocyte-specific deletion of LXRα also compromises RCT and increases atherosclerosis on the Ldlr-null background (Zhang et al., 2012) . Both LXR genes are required for maximal atheroprotection in vivo (Feig et al., 2010) . Nonetheless, synthetic LXR agonists reduce atherosclerosis in both global LXRα-null mice (on an Apoe-null background) and hepatocyte-specific LXRα-null mice (on an Ldlr-null background), and do so without inducing hypertriglyceridemia or hepatic steatosis (Bradley et al., 2007; Zhang et al., 2012) . This suggests that LXRβ-selective agonists may prove efficacious as well as safe as atheroprotective agents. Contrary to this, however, is one report that synthetic LXR agonists reduce aortic atherosclerosis as assessed by en face analysis in Ldlr knockout and Ldlr/Lxrb double knockout mice, but not in Ldlr/Lxra double knockout mice (Bischoff et al., 2010) . Activation of hepatic LXRβ also has the potential to induce steatosis (Korach-Andre & Gustafsson, 2015) . Given this, avoidance of all hepatic LXR activation may possibly be required to avoid liver complications.
Investigations to determine the tissue site of LXR activity in atheroprotection have taught us critical lessons. Selective hematopoietic (macrophage) LXR deletion induced by bone marrow transplantation in mice increases atherosclerosis on both Apoe-null and Ldlr-null backgrounds (Levin et al., 2005; Tangirala et al., 2002) , and impairs atherosclerotic plaque regression (Feig et al., 2010) . Atherosclerosis inhibition by TO901317 in Ldlr-null mice is abolished in the setting of hematopoietic LXR deficiency (Levin et al., 2005) , and GW3965-induced mobilization of cholesterol is attenuated from LXR-null macrophages transplanted into wild type mice (Yasuda et al., 2010) . Collectively, these studies suggest that macrophage LXR is anti-atherogenic and is required for a full in vivo RCT and atheroprotective response to synthetic LXR agonists. On the other hand, cell transplantation studies indicate that macrophage LXR is not sufficient (i.e., in an otherwise LXR-null host) to substantially promote RCT in response to LXR agonists (Yasuda et al., 2010) .
Interestingly, emerging reports suggest that the intestine is a major target tissue in LXR agonist-induced RCT and atheroprotection. LXR agonists dramatically increase TICE van der Veen et al., 2009) , potentially by upregulating the intestinal ABCG5/ABCG8 cholesterol exporter and downregulating intestinal NPC1L1. Selective transgenic overexpression of LXRα in the intestines of mice not only reduces cholesterol absorption and increases plasma HDL, but also enhances RCT from macrophage to feces and reduces atherosclerosis; by contrast, selective overexpression of hepatic LXRα induces hepatic steatosis and hypertriglyceridemia without increasing RCT (Lo Sasso et al., 2010) . LXR agonists increase plasma HDL via activity on intestinal ABCA1 (Brunham et al., 2006) . However, this may not be a critical driver of increased RCT given that LXR agonists reduce atherosclerosis in atherogenic mouse models despite not raising HDL, and HDL-deficient apoAI-null and ABCA1-null mice have intact cholesterol disposal (Temel & Brown, 2015) .
Taken together, important roles have been demonstrated for both LXR proteins in several cell types along the RCT pathway. Nonetheless, it does not appear necessary to activate LXR pharmacologically at all steps along the RCT pathway in order to achieve effective RCT and atheroprotection. In principle, avoidance of hepatic LXR activation may avert complicating steatosis without significant compromise to RCT, and, as discussed below, selective activation of intestinal LXR holds promise as an effective strategy. What remains unclear is to what extent selective activation of intestinal LXR will prove efficacious against inflammatory disorders other than atherosclerosis.
LXR agonists in preclinical models of inflammatory disease
Anti-inflammatory mechanisms of LXRs
Although originally identified for their role in cholesterol homeostasis, the LXRs, like other NRs (e.g., the glucocorticoid receptor), are now known to suppress inflammation, and thus represent ripe targets for anti-inflammatory drug development. The LXRs suppress inflammation through multiple mechanisms, direct and indirect, some involving transactivation and others, transrepression. The relative importance of these mechanisms in specific cell types and during specific disease states remains uncertain.
Tontonoz and colleagues were the first to identify that LXR activation suppresses NF-κB-dependent pro-inflammatory gene induction by lipopolysaccharide (LPS) (Joseph, Castrillo, Laffitte, Mangelsdorf, & Tontonoz, 2003) . As discussed above, this effect, along with suppression of AP-1-and STAT1-dependent pro-inflammatory genes, may stem from transrepression (i.e., tethering of co-repressor complexes to gene promoters by SUMOylated LXR). While a recent report has challenged the importance of LXR SUMOylation, suggesting instead that LXR suppresses TLR4 signaling by depleting cholesterol in lipid rafts via ABCA1 transactivation (Ito et al., 2015) , another group has reported that the anti-inflammatory activity of LXR agonists is intact or even increased in Abca1 −/− Abcg1 −/− macrophages (Kappus et al., 2014) . On other fronts, LXR supports anti-inflammatory programming of macrophages by directly inducing IL-5 (Chen et al., 2012) and the efferocytosis receptor Mer (A-Gonzalez et al., 2009) , and indirectly promoting arginase induction (Pourcet et al., 2011) . Activation of LXR in macrophages upon internalization of cell corpses induces Mer in a feed-forward fashion, and thereby plays a key role in anti-inflammatory clearance of senescent neutrophils and control of the hematopoietic niche in the bone marrow (Casanova-Acebes et al., 2013) . In addition to macrophages, the LXRs modulate inflammatory functions in other leukocyte types. Systemic treatment of mice with TO901317 inhibits chemokine-directed neutrophil migration, although it is unclear if this is LXR-dependent (Smoak et al., 2008) . LXR activation in tissue phagocytes during clearance of senescent neutrophils also plays a pivotal role in neutrophil homeostasis by repressing an IL-23/ IL-17/G-CSF granulopoietic cytokine cascade (Hong, Kidani, et al., 2012) . In lymphocytes, LXR agonists reduce transcription of IL-17 and T helper 1 cytokines (Cui et al., 2011; Walcher et al., 2006) , suppress cell proliferation (Geyeregger et al., 2009) , and inhibit chemokinedirected migration (Walcher et al., 2010) . LXRα activation also suppresses trafficking of mature dendritic cells from tumors to lymph nodes in mice by reducing expression of CC chemokine receptor-7 (CCR7) (Villablanca et al., 2010) , and inhibits LPS-induced functional maturation of dendritic cells (Geyeregger et al., 2007) . Surprisingly, LXR activation is reported to upregulate Ccr7 in immature human dendritic cells and in murine monocyte-derived cells, and to promote migration of the latter from atherosclerotic plaques (Feig et al., 2010) .
LXR also modulates inflammation through transcriptional reprogramming of lipid metabolism. Plasma HDL, which is increased in vivo in response to LXR agonists, inhibits pro-inflammatory TLR signaling in macrophages and myeloproliferative cytokine signaling in bone marrow progenitors by depleting lipid raft cholesterol (Azzam & Fessler, 2012; Fessler & Parks, 2011) . HDL also suppresses proinflammatory gene expression through induction of activating transcription factor 3 (De Nardo et al., 2014) . In macrophages, LXRs induce anti-inflammatory omega-3 polyunsaturated fatty acids via upregulation of genes that mediate elongation and unsaturation of fatty acids (Li et al., 2013) . In hepatocytes, induction of lysophosphatidylcholine acyltransferase 3 (Lpcat3) by LXRα reduces ER stress and associated cytokine induction via incorporation of polyunsaturated fatty acids into cellular phospholipids (Rong et al., 2013) .
Efficacy of LXR agonists in disease models
LXR agonists have now been shown to ameliorate pathology in multiple preclinical rodent models of inflammatory disease (Table 1) . Most studies to date have used the first-generation dual LXRα/β agonists TO901317 and GW3965. Given this, the generalizability of these findings to advanced LXR therapeutics (discussed below) is uncertain, and in many cases even the specificity of the observed effects for LXRs remains unproven.
Of note, while anti-inflammatory efficacy has been demonstrated for LXR agonists in a wide range of disorders, in at least two disease models -collagen-induced arthritis (CIA; a rodent model for rheumatoid arthritis) and ovalbumin sensitization/challenge (a rodent model for allergic asthma) -divergent results have been reported (Table 1) . Two groups have shown that GW3965 reduces the incidence and severity of CIA in DBA/1 mice (Huang et al., 2015; Park et al., 2010) . By contrast, another group has shown that TO90137 and GW3965 exacerbate CIA in DBA/1 mice (Asquith et al., 2009) , and that GW3965 worsens clinical and histopathological severity in C57BL/6 wild type but not LXRα
, or LXRα/β −/− mice (Asquith et al., 2011) . Technical discrepancies presumably account for these differences. In an ovalbumin model of asthma in BALB/C mice, GW3965 was reported to worsen airway hyperresponsiveness without affecting inflammation (Birrell et al., 2008) . By contrast, another group has shown that LXR-null mice from a different genetic background have reduced eosinophilic inflammation, mucus, and airway hyperresponsiveness in both the ovalbumin and house dust mite models of asthma, whereas GW3965 aggravates eosinophilia (Smet et al., 2016) . (Fowler et al., 2003) AHR, airway hyperresponsiveness; APP, amyloid precursor protein; ASM, airway smooth muscle; DSS, dextran sulfate sodium; EAE, experimental autoimmune encephalomyelitis; HDM, house dust mite; Ig, immunoglobulin; LPS, lipopolysaccharide; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MS, multiple sclerosis; OVA, ovalbumin sensitization and challenge; PS-1, presenilin-1; STZ, streptozotocin; tg, transgenic mouse; TNBS, 2,4,6-Trinitrobenzenesulfonic acid. a This table lists select reports of GW3965 and TO901317 efficacy across preclinical inflammatory disease models.
Caution is warranted in extrapolating results derived from rodent models to humans. Importantly, TLR4 is a direct target gene in human, but not rodent cells; thus, LXR agonists upregulate TLR4 in primary human macrophages and augment LPS induction of pro-inflammatory genes in human macrophages and dendritic cells (Fontaine et al., 2007; Torocsik et al., 2010) . Augmentation of inflammation in macrophages is dependent on the duration of pretreatment with LXR agonist, with b12 h pretreatment inhibiting, but 24-48 h pretreatment augmenting LPS-induced cytokines (Fontaine et al., 2007) . LXR regulation of eicosanoids also differs between murine and human cells. Whereas LXR agonists reduce LPS induction of prostaglandin E2 in mouse macrophages potentially through Lpcat3-dependent effects on arachidonic acid availability (Rong et al., 2013) , LXR-induced Lpcat3 enhances LPSinduced eicosanoid release from human macrophages (Ishibashi et al., 2013) .
Finally, another important in vivo difference between rodent and primate LXRs lies in induction in the liver of the LXR target IDOL, an E3 ubiquitin ligase that induces degradation of LDLR and family members VLDLR and apoER2 (Hong et al., 2010) . Hepatic LDLR is a major clearance site for plasma LDL and thus a key determinant of plasma LDL levels. In mice, LXR induces Idol in peripheral tissues (e.g., macrophages) but not in liver, and thus does not alter plasma LDL; by contrast, in cynomolgus monkeys, LXR agonists induce hepatic IDOL, and thereby reduce LDLR protein levels, elevating plasma LDL . The increase in LDL-cholesterol in non-human primates (and its potential to occur in humans) may also be driven by induction of CETP, an LXR target gene expressed in primates but not mice. CETP supports transfer of cholesterol ester from HDL to LDL particles (Fig. 2) . Clearly, more work will be required to define species-and context-specific effects of LXR agonists. In principle, dual LXR therapies such as co-treatment with a hepatic IDOL antagonist and/or a statin could be tested. Of interest, it was recently shown that co-treatment of mice with the peroxisome proliferator-activated receptor (PPAR)α agonist fenofibrate neutralized the hepatic steatosis and hypertriglyceridemia induced by an LXR agonist (Boergesen et al., 2012) .
Advanced LXR therapeutics
In recent years, several pharmacological attempts have been made to harness the pro-RCT and anti-inflammatory actions of LXR agonists without activating hepatic LXRα (and thereby causing hepatic steatosis, hypertriglyceridemia, and elevated LDL-cholesterol in primates). These include: i) LXRβ-selective agonists; ii) tissue-selective LXR agonists; and iii) transrepression-selective LXR agonists. To date, four synthetic LXR agonists have entered phase I clinical trials, most of these with the ultimate aim of treating atherosclerosis Ma et al., 2017) . These agents are: LXR-623 (Wyeth Pharmaceuticalsnow Pfizer); CS-8080 (Daichii Sankyo); BMS-779788 (XL-652; Exelixis and Bristol-Myers Squibb); and BMS-852927 (XL-041; Exelixis and Bristol-Myers Squibb). Unfortunately, none of these drugs have progressed, either due to adverse effects (LXR-623, BMS-852927) as discussed below, or for other reasons (not disclosed by sponsor). A fifth agent, VTP-38543 (Vitae Pharmaceuticals -now Allergan), was tested recently in a phase IIa trial for topical treatment of mild-to-moderate atopic dermatitis (ClinicalTrials.gov identifier: NCT02655679). The trial has been completed but the results are yet to be disclosed.
LXRβ-selective agonists
Recent efforts in industry have yielded several agonists with relative selectivity for LXRβ over LXRα. Selective carboxylic acid-based quinoline agonists were developed, but proved to have PPAR agonism (Hu et al., 2008) . Quinolone-3-carboxamide-containing sulfones with good LXRβ-selectivity were developed but found to have an insufficient dose window between ABCA1 upregulation in macrophages versus triglyceride accumulation in hepatocytes (Hu, Bernotas, et al., 2010) .
Additional agents identified to have LXRβ-selectivity include cinnolines/quinolines and N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylproprionamides (Hu et al., 2009; Swahn et al., 2009) , among other molecules.
LXRβ-selective agents have recently been tested in human subjects. The first was LXR-623, an agonist with modest (~7-fold) selectivity for LXRβ which had been shown to reduce atherosclerosis in Ldlr-null mice without hepatic lipogenesis and to reduce plasma LDLcholesterol in non-human primates with only transient effects on plasma triglycerides (Quinet et al., 2009) . In a single ascending dose study in humans, although LXR-623 did increase LXR target gene expression in peripheral blood cells, it was associated with central nervous system and psychiatric adverse events at the two highest doses, precluding further development (Katz et al., 2009) . It remains unclear whether this was an off-target effect, or LXR-mediated. On other fronts, introduction of a substituted phenylsulfone into a series of biphenyl imidazole LXR agonists was recently reported to yield two novel LXRβ-selective partial agonists, BMS-779788 and BMS-852927, with a therapeutic window (i.e., blood cell ABCG1 upregulation but modest elevation of plasma triglycerides) in cynomolgus monkeys (Kick et al., 2016; Kirchgessner et al., 2015) . Of these, testing of BMS-779788 in a phase I clinical trial was completed (ClinicalTrials.gov identifier: NCT00836602), but the results have not been disclosed. For BMS-852927, a wide therapeutic index in cynomolgus monkeys and mice and successful induction of RCT genes in peripheral blood of healthy subjects and hypercholesterolemic patients was observed. Despite this, increased plasma and hepatic triglyceride, increased plasma LDL-cholesterol, and decreased circulating neutrophils -effects not initially predicted by the preclinical monkey model -were observed in human volunteers in a phase I clinical study (Kirchgessner et al., 2016) .
Recently, the application of structure-based drug design technology to a phenylsulfone fragment led to development of a novel, orally bioavailable LXRβ-selective partial agonist (Zheng et al., 2016) . This prototype has reportedly been further optimized for human trials (Zheng et al., 2016) .
Tissue-selective agonists
One of the most promising areas in LXR drug development is tissueselective LXR activation. In some cases, tissue selectivity has been conferred through pharmacologic strategies (e.g., drug inactivation in plasma, low blood-brain barrier penetration, cell-specific uptake), whereas in others, specificity arises from tissue-or even gene-specific interaction of the LXR/agonist complex with differential co-activators/co-repressors. On the latter note, a recent study has shown that the co-activator thyroid hormone receptor-associated protein 80 (TRAP80) selectively promotes transcription of SREBP-1c but not ABCA1 in hepatic cell lines and that liver-selective knockdown of TRAP80 in mice ameliorates the hepatic steatosis and hypertriglyceridemia induced by an LXR agonist without impairing RCT stimulation .
Selective activation of LXR in the intestine is particularly promising as it carries the potential to decrease dietary cholesterol absorption (via reduced intestinal NPC1L1 and increased intestinal ABCG5/ ABCG8), increase plasma HDL (via increased intestinal ABCA1), and increase RCT, all in the absence of hepatic steatosis (Lo Sasso et al., 2010) . GW6340, an intestine-specific ester version of the LXR agonist GW3965, was shown to promote fecal excretion of macrophage-derived cholesterol (i.e., RCT) in mice without changing hepatic LXR target genes or hepatic triglyceride content, although the magnitude of RCT was less than that induced by GW3965 (Yasuda et al., 2010) . YT-32, a phytosterol derivative [(22E)-ergost-22-ene-1α,3β-diol] LXRα/β agonist, was also shown to selectively activate intestinal LXR target genes in mice upon oral administration, thereby reducing cholesterol absorption without increasing plasma triglycerides (Kaneko et al., 2003) .
WYE-672, a phenylsulfone-substituted quinoxaline, is an LXRβ-selective agonist with tissue-selectivity, activating LXRβ in kidney (HEK293) cells and macrophages (THP-1), but not liver cells (huh-7) ; treatment of Ldlr-null mice reduced aortic arch atherosclerosis with no plasma or hepatic triglyceride increase (Hu, Unwalla, et al., 2010) . Generally similar findings were noted for ATI-829, a potent synthetic steroidal LXR agonist which induced ABCA1 robustly in THP-1 macrophages but SREBP-1c to only a minor extent in HepG2 hepatoma cells; treatment of Ldlr-null mice activated LXR target genes in intestine and macrophages but not liver, reducing atherosclerosis without hepatic or plasma triglyceride increase (Peng et al., 2008) .
Finally, alternative LXR agonist formulations have recently succeeded in tissue-selective drug delivery. In a recent immunologically targeted strategy, an aminooxy-modified LXR agonist conjugated to anti-CD11a IgG achieved potent, macrophage-selective LXR activation without a significant effect in hepatocytes (Lim et al., 2015) . Nanoparticle formulations containing GW3965 have recently also been shown to have increased anti-inflammatory potency against macrophagemediated inflammation in vitro and in vivo, with systemic injection achieving effective uptake by atherosclerotic plaque macrophages with negligible induction of lipogenic genes in the liver (Gadde et al., 2014; Zhang et al., 2015) . Although intestinal-specific LXR agonists may in principle suppress inflammation in peripheral macrophages by increasing plasma HDL, direct activation of macrophage LXR may have greater anti-inflammatory effect.
Transrepression-dissociated agonists
LXR agonists have recently been developed that dissociate transrepression from target gene transactivation in an effort to selectively harness the anti-inflammatory activity of LXRs (Fig. 1) . As an example, structure-guided design of N-phenyl tertiary amines using the crystal structure of TO901317 bound to LXRβ led to the identification of a compound, GSK9772, with N10-fold selectivity for transrepression over transactivation (Chao et al., 2008) . GSK9772 suppressed LPS-induced iNOS and IL-6 through a mechanism involving LXRβ SUMOylation and inhibition of NCoR clearance, and did so with only very weak transactivation of ABCA1 and SREBP1c (Chao et al., 2008) . N,N-dimethyl-3β-hydroxycholenamide (DMHCA), a steroidal LXR agonist, and its more potent analog, methylpiperidinyl-3β-hydroxycholenamide (MePipHCA), both reduce inflammation in colitis and traumatic brain injury models without inducing hepatic steatosis (Yu et al., 2016) . The minimal induction of lipogenic genes by DMHCA stems not from its inefficacy at transactivation but rather from its inhibition of the lipogenic transcription factor SREBP-1c (Yu et al., 2016) . This likely arises from its structural similarity to desmosterol, a native cholesterol pathway intermediate with coordinate LXR agonism and SREBP inhibitory activity. Interestingly, DMHCA also reportedly increases desmosterol levels and reduces cholesterol through inhibiting the cholesterol biosynthetic enzyme 3β-hydroxysterol-Δ24-reductase (Pfeifer et al., 2011) . In an analogous vein, ATI-111, a steroidal LXR agonist modified from ATI-829 (discussed above), was reported to reduce atherosclerosis in Ldlr-null mice while lowering plasma triglycerides, potentially also through inhibition of SREBP-1c activation (Peng et al., 2011) . Taken together, DMHCA and ATI-111 dissociate transactivation of RCT-active LXR target genes from lipogenic LXR target genes by blocking processing of the LXR target SREBP-1c. In this regard, they are similar to native LXR agonists (desmosterol and oxysterols), which coordinately inhibit SREBP activation through actions in the ER (Fessler, 2016) .
LXR inverse agonists and antagonists
Recently, potential applications for inhibition of LXR have been proposed. Non-alcoholic fatty liver disease is a common condition that in its more severe form can progress to steatohepatitis and cirrhosis (Vizuete, Camero, Malakouti, Garapati, & Gutierrez, 2017) . There is currently no specific, proven effective pharmacological therapy. Recently, SR9238, a liver-selective (due to inclusion of an ester group labile to plasma enzymes) dual LXRα/β inverse agonist was shown to suppress hepatic lipid accumulation and inflammation in a mouse model of nonalcoholic hepatosteatosis, suggesting potential application to human fatty liver disease (Griffett, Solt, El-Gendy Bel, Kamenecka, & Burris, 2013) . On a different front, it was recently shown that the LXR antagonist GSK2033 suppresses dexamethasone-induced upregulation of gluconeogenic genes (i.e., phosphoenolpyruvate carboxykinase [Pepck] ) in liver cells without attenuating dexamethasone antiinflammatory effects; this effect arises from inhibition of LXRβ-dependent recruitment of the glucocorticoid receptor to the Pepck promoter (Patel et al., 2017) . Moreover, LXR antagonism reduced dexamethasone-induced hepatic steatosis (Patel et al., 2011 (Patel et al., , 2017 . This suggests potential for adjunctive use of LXR antagonists during glucocorticoid therapy in order to attenuate the metabolic side effects of glucocorticoids while preserving anti-inflammatory efficacy. On an analogous front, bexarotene, an RXR agonist, has been used as a therapy for refractory cutaneous T-cell lymphoma, but induces complicating hypertriglyceridemia in the majority of patients (Huen & Kim, 2015) . It was recently reported that bexarotene-induced hypertriglyceridemia and hepatic steatosis are abrogated in LXR-null mice; this is due to bexarotene-induced recruitment of RXRs to LXREs (via permissive LXR heterodimerization) in the promoters of lipogeneic genes in the liver, including Srebp-1c and fatty acid synthase (Lalloyer et al., 2009 ). This suggests the possibility that LXR antagonists may be useful adjuncts during bexarotene therapy.
Inhibition of hepatic LXR has the potential to impair RCT (through downregulation of hepatic ABCA1, ABCG5, and ABCG8) and thereby theoretically aggravate atherosclerosis. Given this, it remains unclear whether LXR antagonism will prove a safe pharmacological strategy in humans. Indeed, increased plasma levels of 25-hydroxycholesterol-3-sulfate, a native metabolite with antagonistic activity on LXR, are found in patients with obesity and metabolic syndrome .
Conclusions and future perspectives
Studied now for~20 years, the LXRs have posed exciting potential opportunities for the therapy of atherosclerosis and a growing number of inflammatory diseases, but have so far eluded successful translation to humans. Recently, several advanced pharmacologic strategies have been pursued, including LXRβ-selective agonists, tissue-selective LXR agonists, and transrepression-selective LXR agonists, among others. Several of these more selective strategies appear promising, although early studies in humans with some of these agents have unfortunately been complicated by adverse effects not predicted even by nonhuman primate models. Non-systemic routes of drug delivery with reduced risk for toxicity (e.g., topical administration) are also under study, and have not yet been comprehensively explored. In addition, dual therapy of LXR agonists with other agents that mitigate lipogenesis (e.g., IDOL antagonists) remain as possibilities. As testing of LXR agonists in preclinical disease models and structure-guided drug development both continue, it appears likely that effective and safe applications for LXR targeting in human disease will ultimately be realized.
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